Markets / Mutual funds / Index Funds (equity)
Tata Mutual Fund · Index & ETFs fund · Regular plan · IDCW
The investment objective of the scheme is to provide returns, before expenses, that are in line with the performance of Nifty MidSmall Healthcare Index (TRI), subject to tracking error. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The scheme does not assure or guarantee any returns
Bars: this plan; the thin mark is the Index Funds (equity) average (regular plans, growth option). Over a year: yearly averages (CAGR). Past returns do not guarantee future returns. Information only, not investment advice.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | +2.9 | |||||||||||
| 2025 | -7.4 | -7.7 | +10.0 | -0.9 | +1.7 | +4.5 | +5.3 | -4.6 | -0.5 | +2.0 | +0.3 | -0.9 |
| 2026 | -5.0 | +5.3 | -5.2 | +7.8 | +6.2 | +4.9 | +3.1 | +1.5 | -3.1 | +1.8 | +2.0 |
Each month's change in NAV (the current month to the latest NAV).
Worked out from this plan's actual NAVs. SIP: invested on the first NAV of each month. Taxes and exit loads are not included. Past returns do not guarantee future returns. Information only, not investment advice.
| Share of fund | 31 Oct 2026 | 30 Sept 2026 | Change |
|---|---|---|---|
| Stocks held | 100.2% | 100.1% | +0.08 |
| Cash & others | 0.1% | 0.1% | -0.08 |
| Top 10 stocks | 60.1% | 58.8% | +1.28 |
| Number of stocks | 30 | 30 | 0 |
Change is in percentage points. Bought more and cut back list stocks whose share of the fund moved by at least 0.25 points. A share can also move because the price changed, not only because the fund traded.
| Holding | % of fund |
|---|---|
| LAURUS LABS LTD INE947Q01028 | 14.12% |
| LUPIN LTD INE326A01037 | 7.36% |
| AUROBINDO PHARMA LTD INE406A01037 | 7.00% |
| FORTIS HEALTHCARE LTD INE061F01013 | 6.03% |
| GLENMARK PHARMACEUTICALS LTD INE935A01035 | 5.22% |
| ALKEM LABORATORIES LTD INE540L01014 | 4.65% |
| MANKIND PHARMA LTD INE634S01028 | 4.26% |
| IPCA LABORATORIES LTD INE571A01038 | 4.04% |
| GLAND PHARMA LTD INE068V01023 | 3.72% |
| BIOCON LTD INE376G01013 | 3.70% |
| SAI LIFE SCIENCES LTD INE570L01029 | 3.25% |
| ACUTAAS CHEMICALS LTD INE00FF01025 | 3.13% |
| KRISHNA INSTITUTE OF MEDICAL SCIENCES LTD INE967H01025 | 2.82% |
| ASTER DM QUALITY CARE LTD INE914M01019 | 2.74% |
| NEULAND LABORATORIES LTD INE794A01010 | 2.56% |
| AJANTA PHARMA LTD INE031B01049 | 2.41% |
| WOCKHARDT LTD INE049B01025 | 2.37% |
| DR. LAL PATH LABS LTD INE600L01024 | 2.24% |
| PIRAMAL PHARMA LTD INE0DK501011 | 2.24% |
| ABBOTT INDIA LTD INE358A01014 | 2.01% |
| GRANULES INDIA LTD INE101D01020 | 1.87% |
| ONESOURCE SPECIALTY PHARMA LTD INE013P01021 | 1.85% |
| NARAYANA HRUDAYALAYA LTD INE410P01011 | 1.79% |
| GLOBAL HEALTH LTD INE474Q01031 | 1.70% |
| GLAXOSMITHKLINE PHARMACEUTICALS LTD INE159A01016 | 1.56% |
| ANTHEM BIOSCIENCES LTD INE0CZ201020 | 1.35% |
| NATCO PHARMA LTD INE987B01026 | 1.16% |
| SYNGENE INTERNATIONAL LTD INE398R01022 | 1.15% |
| COHANCE LIFESCIENCES LTD INE03QK01018 | 1.09% |
| POLY MEDICURE LTD INE205C01021 | 0.83% |
| Holding | % of fund |
|---|---|
| I) REPO | 0.05% |
From the fund house's monthly portfolio (tatamutualfund.com), as on 31 Oct 2026. Percentages are of the fund's net assets. Published about ten days after each month ends.
Volatility: how much the NAV moves, as a yearly figure (higher = bumpier). Worst fall: the biggest drop from a high, in the NAV history we hold (from 3 May 2024).
| Fund size (average AUM, July - September 2026) | ₹210 cr across all plans |
| Fund house | Tata Mutual Fund |
| Category | Index & ETFs · Index Funds (equity) |
| Plan | Regular |
| Option | IDCW |
| Expense ratio (TER) | Direct 0.59% · Regular 1.15% (5 Nov 2026) |
| Exit load | 0.25% of the applicable NAV, if redeemed on or before 15 days from the date of allotment. |
| Minimum investment | ₹5,000 · additional ₹1,000 |
| Scheme code (AMFI) | 152562 |
| ISIN | INF277KA1BE8 |
| NAV date | 5 Nov 2026 |
Scheme details from the fund's scheme summary document filed with AMFI; expense ratios from AMFI's daily filings.
| Plan | NAV | 1 year |
|---|---|---|
| Direct · Growth | ₹15.5457 | +18.73% |
| Direct · IDCW | ₹15.5457 | +18.73% |
| Direct · IDCW | ₹15.5457 | +18.73% |
| Regular · Growth | ₹15.2932 | +18.01% |
| Regular · IDCW | ₹15.2932 | +18.01% |
| Fund | 1 year | 3 years (a year) |
|---|---|---|
| ICICI Prudential NASDAQ 100 Index Fund | +10.81% | +25.41% |
| Motilal Oswal S&P 500 Index Fund | +15.40% | +23.79% |
| ICICI Prudential Nifty Pharma Index Fund | +22.94% | +22.18% |
| Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund | +21.72% | +21.26% |
| Motilal Oswal BSE Enhanced Value Index Fund | -2.47% | +19.95% |
| UTI Nifty 500 Value 50 Index Fund | +2.35% | +19.85% |
| ICICI Prudential Nifty Auto Index Fund | +3.82% | +19.65% |
| Motilal Oswal BSE Enhanced Value Index Fund | -3.11% | +19.14% |
All Index Funds (equity) funds ranked › · Compare with others ›
Information only, not investment advice.
₹15.2932 as of 5 Nov 2026, from AMFI's official NAV data.
1 year: 18.01%
Both invest in the same portfolio. Direct plans are bought straight from the fund house and pay no distributor commission, so their expenses are lower and their NAV grows slightly faster.